Which CDKI Works Best? A Real World Look at Palbociclib and Ribociclib

Imagine you're at the doctor's office, trying to figure out which medicine works best for a specific type of breast cancer. Palbociclib and ribociclib are both used to treat HR-positive, HER2-negative metastatic breast cancer, but which one is more effective? A study called OPAL (NCT03417115) tried to answer this question. They looked at how long patients stayed disease-free (progression-free survival or PFS) and how long they lived (overall survival or OS) after starting treatment with either palbociclib plus endocrine therapy (PALBO) or ribociclib with endocrine therapy (RIBO).

The study included 623 patients who had received either PALBO or RIBO as their first treatment. The results showed no major difference in PFS or OS between the two treatments. The median PFS for PALBO was 26. 7 months, and for RIBO, it was 27. 0 months. Similarly, the median OS was 42. 4 months for PALBO and 49. 3 months for RIBO. However, patients who started treatment within a year of their previous therapy (known as TFI

Actions